Literature DB >> 19890336

Therapy for metastatic RCC--questions remain.

Rodney H Breau, Bradley C Leibovich.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19890336     DOI: 10.1038/nrurol.2009.210

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Renal-cell carcinoma--molecular pathways and therapies.

Authors:  James Brugarolas
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 4.  Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy.

Authors:  Paul Russo; Matthew Francis O'Brien
Journal:  Urol Clin North Am       Date:  2008-11       Impact factor: 2.241

5.  Sequential sorafenib and sunitinib for renal cell carcinoma.

Authors:  M P Sablin; S Negrier; A Ravaud; S Oudard; C Balleyguier; J Gautier; C Celier; J Medioni; B Escudier
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

6.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

8.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321

9.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Authors:  G Fyfe; R I Fisher; S A Rosenberg; M Sznol; D R Parkinson; A C Louie
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

  9 in total
  1 in total

1.  New insights into long noncoding RNAs and pseudogenes in prognosis of renal cell carcinoma.

Authors:  Binghai Chen; Chengyue Wang; Jin Zhang; Yang Zhou; Wei Hu; Tao Guo
Journal:  Cancer Cell Int       Date:  2018-10-11       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.